Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Gold/Mining/Energy : Nuvo Research Inc -- Ignore unavailable to you. Want to Upgrade?

To: axial who wrote (13951)	2/7/2005 11:12:10 AM
From: Cal Gary	Respond to of 14101

Kudos to Dan, John and team. "Two birds with one stone" Perhaps the two birds were related?!!

To: axial who wrote (13951)	7/7/2005 2:01:56 PM
From: Cal Gary	Read Replies (1) \| Respond to of 14101

Dimethaid improves Pennsaid formula Dimethaid Research Inc (TSX:DMX) Shares Issued 122,512,820 Last Close 7/6/2005 $0.26 Thursday July 07 2005 - News Release Mr. Peter Block reports DIMETHAID DEVELOPS "PENNSAID(R) PLUS": AN INNOVATIVE NEW FORMULATION FOR PENNSAID(R) -- COMPANY ALSO RETAINS SPECIALIZED CONSULTANT FOR INTERNATIONAL PRODUCT LICENSING Dimethaid Research Inc. has developed a new formulation for its topical osteoarthritis product, Pennsaid. The new formulation, called Pennsaid Plus, allows for faster penetration of the active ingredient, diclofenac, to the treatment area. "This is a very significant development for the company and for those who use Pennsaid," said Dr. Henrich Guntermann, president and chief executive officer of Dimethaid. "With this new formulation, we anticipate that the faster penetration will result in a reduced dosage application. We also anticipate less skin irritation due to an improved humectant being added to the formula. We are taking an effective and safe product and making it even better." The company anticipates that it will take three to five years to obtain approval of Pennsaid Plus by regulatory authorities in United States, Canada and Europe. During this time, the company will be conducting clinical trials to demonstrate the new product's safety and efficacy. The original Pennsaid continues to capture increased market share in Canada, and is also approved for sale in the United Kingdom, as well as a number of other European and Caribbean countries. The company is continuing its strategy to seek regulatory approval for the original Pennsaid in those key markets where approval has yet to be granted, including the U.S. As previously disclosed, the company anticipates submitting its amended new drug application to the U.S. Food and Drug Administration by mid-2006. Dimethaid has also retained Diane Kalina to pursue international licensing agreements for its products, including Pennsaid and Pennsaid Plus. Ms. Kalina will be a consultant to the company. "Diane is a seasoned executive and is considered one of the Canadian industry's foremost licensing experts," said Dan Chicoine, chairman of Dimethaid. "We see considerable international opportunity for our products that we have yet to aggressively pursue. This is a key step in our strategy of seeking partners for our pipeline of products." Ms. Kalina has over 27 years experience in the industry, of which 16 were with Glaxo Canada (now GlaxoSmithKline) and included the positions of head of marketing, and director of new products and licensing. While at Glaxo she was responsible for the in-licensing of 3TC, a pivotal drug for AIDS therapy, now with worldwide sales of $982-million (U.S.). She has since negotiated over 60 major agreements covering technology transfer, biotech in- and out-licensing, joint developments, mergers, divestitures and acquisitions. © 2005 Canjex Publishing Ltd.